Side-by-side · Research reference

HGH 191AAvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED0/75 cited

BPhase 2HUMAN-REVIEWED10/41 cited

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

HGH 191AA

Retatrutide

Primary target

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

—

Origin

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

Rare — <2% develop binding antibodies, typically non-neutralizing

—

02Dosage Protocols

Parameter

HGH 191AA

Retatrutide

Pediatric GHD

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

—

Adult GHD

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

—

Turner syndrome

0.045–0.050 mg/kg/day SQ

—

Idiopathic short stature

0.037 mg/kg/day SQ

—

AIDS wasting

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

—

Frequency

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Once weekly

Evidence basis

FDA-approved / decades of RCT data

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Monitoring

IGF-1, glucose, thyroid function, bone age (children)

—

Duration

Years (children until epiphyseal closure); indefinite (adult GHD)

Indefinite for chronic indication (presumed)

Standard dose

—

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

03Metabolic / Fat Loss Evidence

Parameter

HGH 191AA

Retatrutide

Primary fat target

Visceral and subcutaneous adipose tissue

—

Mechanism

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

—

Effect on lean mass

Significant lean mass increase (protein synthesis, nitrogen retention)

—

Insulin sensitivity

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

—

IGF-1 elevation

Dose-dependent, significant — primary anabolic mediator

—

Glucose metabolism

Hyperglycemia risk, especially high doses (AIDS wasting)

—

Body composition

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

—

Clinical context

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

—

04Side Effects & Safety

Parameter

HGH 191AA

Retatrutide

Injection site reaction

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

—

Glucose intolerance

Hyperglycemia, new-onset diabetes (anti-insulin effect)

—

Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

—

Slipped capital femoral epiphysis

SCFE risk in children — limp, hip/knee pain (requires surgery)

—

Scoliosis progression

Rapid growth may unmask/progress scoliosis (monitor spine in children)

—

Hypothyroidism

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

—

Cancer risk

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

—

Antibody formation

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

—

Pancreatitis

Rare. Higher risk in children with certain syndromes (Prader-Willi).

—

Gynecomastia

Adolescent males (physiological during puberty, may be exacerbated)

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

HGH 191AA

Retatrutide

1. Reconstitution (if lyophilized)

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Injection site

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

Once weekly, same day.

4. Storage

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

Refrigerate 2–8 °C. Light-protected.

5. Needle

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

27–31G, 4–8 mm insulin syringe.

6. Monitoring

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

—

06Stack Synergy

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms

Retatrutide

— no documented stacks